P5342 - Risk of Colorectal and Hepatobiliary Cancers in Inflammatory Bowel Disease With and Without Primary Sclerosing Cholangitis: A Propensity-Matched Cohort Analysis

Omar Al Ta’ani, MD¹, Saqr Alsakarneh, MD, MSc², Aasma Shaukat, MD, MPH, FACG³, Francis A.. Farraye, MD, MSc, MACG⁴, Jana G. Hashash, MD, MSc, FACG⁴, Fadi F.. Francis, MD⁴
1Department of Internal Medicine, Allegheny Health Network, Pittsburgh, Pennsylvania, USA, Pittsburgh, PA; 2Mayo Clinic, Rochester, MN; 3NYU Grossman School of Medicine, Division of Gastroenterology and Hepatology, New York, NY; 4Mayo Clinic, Jacksonville, FL

Introduction: Primary sclerosing cholangitis (PSC) is a chronic cholestatic liver disease frequently associated with inflammatory bowel disease (IBD). While both conditions independently increase cancer risk, the comparative burden of cancer in patients with coexisting IBD and PSC (IBD-PSC), isolated IBD, and isolated PSC remains inadequately defined.

Methods: We conducted a retrospective cohort study using the TriNetX nationwide electronic health records database. Patients with IBD-PSC were compared to individuals with isolated IBD and isolated PSC. Propensity score matching (PSM) was employed to balance key baseline characteristics across groups. Adjusted hazard ratios (aHRs) with 95% confidence intervals (CIs) were calculated for intestinal and extraintestinal malignancies across three pairwise comparisons: IBD-PSC vs isolated IBD, IBD-PSC vs isolated PSC, and isolated PSC vs isolated IBD.

Results: There were 4,187 patients in both the IBD-PSC and isolated IBD groups after matching, with minimal residual confounding across demographic and clinical variables (Table 1). Compared to isolated IBD, IBD-PSC was associated with significantly increased risks of colorectal cancer (aHR 4.01, 95% CI 2.79–5.75; p< 0.001), cholangiocarcinoma (aHR 27.54, 95% CI 15.05–50.38; p< 0.001), liver cancer (aHR 13.41, 95% CI 7.42–24.26; p< 0.001), pancreatic cancer (aHR 2.37, 95% CI 1.18–4.76; p=0.013), and gallbladder cancer (aHR 36.26, 95% CI 4.94–266.23; p< 0.001).

Compared to isolated PSC, IBD-PSC showed higher risks of colorectal cancer (aHR 5.72, 95% CI 3.17–10.31; p< 0.001) and gallbladder cancer (aHR 4.14, 95% CI 1.69–10.14; p=0.001), while differences in liver (aHR 1.22, 95% CI 0.86–1.73; p=0.268) and pancreatic cancer (aHR 0.80, 95% CI 0.36–1.77; p=0.583) were not significant. Isolated PSC was associated with a lower risk of rectal cancer compared to isolated IBD (aHR 0.34, 95% CI 0.14–0.85; p=0.015), but with higher risks of cholangiocarcinoma (aHR 14.82, 95% CI 7.78–28.25; p< 0.001), liver (aHR 5.47, 95% CI 3.24–9.23; p< 0.001), pancreatic (aHR 2.56, 95% CI 1.32–4.97; p=0.004), and gallbladder cancer (aHR 9.52, 95% CI 1.21–75.16; p=0.009) as shown in Table 2.

Discussion: IBD-PSC is associated with substantially elevated risks of both intestinal and extraintestinal malignancies compared to isolated IBD or PSC. These findings highlight the synergistic oncogenic potential of coexisting IBD and PSC and underscore the need for tailored surveillance and early detection strategies in this high-risk population.


Figure: Table 1. Baseline Characteristics of Patients with IBD-PSC and Isolated IBD Before and After Propensity Score Matching


Figure: Table 2. Adjusted Hazard Ratios for Intestinal and Extraintestinal Cancers Across IBD-PSC, IBD Alone, and PSC Alone Cohorts

Disclosures:
Omar Al Ta’ani indicated no relevant financial relationships.
Saqr Alsakarneh indicated no relevant financial relationships.
Aasma Shaukat: Freenome inc – Consultant.
Francis Farraye: Astellas – Advisory Committee/Board Member. Avalo – Advisory Committee/Board Member. Bausch – Advisory Committee/Board Member. BMS – Advisory Committee/Board Member. Braintree Labs – Advisory Committee/Board Member. Fresenius Kabi – Advisory Committee/Board Member. GI Reviewers – Independent Contractor. IBD Educational Group – Independent Contractor. Iterative Health – Advisory Committee/Board Member, Stock Options. Janssen – Advisory Committee/Board Member. Lilly – DSMB. Pfizer – Advisory Committee/Board Member. Pharmacosmos – Advisory Committee/Board Member. Sandoz – Advisory Committee/Board Member. Viatris – Advisory Committee/Board Member.
Jana Hashash: BMS – Ad Board.
Fadi Francis indicated no relevant financial relationships.

Omar Al Ta’ani, MD¹, Saqr Alsakarneh, MD, MSc², Aasma Shaukat, MD, MPH, FACG³, Francis A.. Farraye, MD, MSc, MACG⁴, Jana G. Hashash, MD, MSc, FACG⁴, Fadi F.. Francis, MD⁴. P5342 - Risk of Colorectal and Hepatobiliary Cancers in Inflammatory Bowel Disease With and Without Primary Sclerosing Cholangitis: A Propensity-Matched Cohort Analysis, ACG 2025 Annual Scientific Meeting Abstracts. Phoenix, AZ: American College of Gastroenterology.